Pacira shares fall after FDA committee rejects expanded use for Exparel pain drug

Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell nearly -16% today after a panel of experts convened by the FDA voted against an expanded use for Pacira’s injectable pain drug.
The pharmaceutical company previously submitted an application seeking to use the local anesthetic as a regional pain-killer.
Get the full story at our sister site, Drug Delivery Business News.
The post Pacira shares fall after FDA committee rejects expanded use for Exparel pain drug appeared first on MassDevice.

Source: Mass Device - February 16, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Pain Management Pharmaceuticals Regulatory/Compliance Wall Street Beat Pacira Pharmaceuticals Source Type: news